NVST Envista (NVST) Insider Trading, Ownership & Congress Trades
Medical Devices · Dental equipment & supplies · CIK 0001757073
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
203
13F, latest reported quarter
What the filings say about NVST
Insiders, 180 days
-$220.0K net sold
1 seller · 100% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2024-06-06
Planned sales (Form 144), 90 days
$220.0K
1 notice
Envista insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Envista Holdings Corp insiders sold a net $220.0K of stock across 72 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Feb 10, 2026.
- The trade is 29.3% of the 27,321 shares held after it.
- No other insider sold within 30 days.
- 203 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Strategy & Bus. Dev. Reis Mischa sold about $220.0K of NVST under a 10b5-1 plan on Aug 20, 2026; 203 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 25, 2025.
- The trade is 17.4% of the 32,382 shares held after it.
- No other insider sold within 30 days.
- 203 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Strategy & Bus. Dev. Reis Mischa sold about $169.0K of NVST on Feb 10, 2026; 203 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 25, 2025.
- The trade is 12.5% of the 32,382 shares held after it.
- No other insider sold within 30 days.
- 203 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Strategy & Bus. Dev. Reis Mischa sold about $121.2K of NVST on Feb 10, 2026; 203 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Mar 18, 2022.
- The trade is 46.3% of the 32,382 shares held after it.
- No other insider sold within 30 days.
- 203 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Strategy & Bus. Dev. Reis Mischa sold about $324.0K of NVST on Aug 25, 2025, the largest insider sale at the company since 2023; 203 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 7.5% of the 402,605 shares held after it.
- 1 other insider bought within 30 days.
- 203 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Keel Paul A bought about $506.1K of NVST on Aug 13, 2024, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 203 funds added in the latest 13F quarter.72 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$220.0K over 180 days
-$220.0K over 90 days
below 52% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
203 funds bought in last quarter
more than 84% of Medical Devices
Revenue
+8.3% year over year
below 54% of Medical Devices
Margin
1.7% net margin
more than 69% of Medical Devices
Buybacks
no share repurchases reported
Short interest
7.5% of the float short (float per yahoo 2026-10-26) · 3.6 days to cover · settled 2026-09-30
more than 79% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NVST
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+16.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NVST: institutional holders (13F)
13F holdings, latest reported quarter
18,437,542 sh
$485.8M
9,818,177 sh
$258.7M
9,566,949 sh
$252.1M
7,487,670 sh
$197.3M
7,337,916 sh
$193.4M
Congress trades in NVST
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2024-06-06 · disclosed the same day
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NVST planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Reis Mischa
Filed 2026-08-20
$220.0K
NVST mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Clarkston Partners Fund
$11.9M position · as of 2026-06-30
4.1%
Victory Investment Grade Convertible Fund
$9.0M position · as of 2026-06-30
3.7%
Ariel Fund
$89.2M position · as of 2026-06-30
3.1%
Clarkston Founders Fund
$2.1M position · as of 2026-06-30
2.9%
Heartland Value Plus Fund
$8.6M position · as of 2026-06-30
2.6%
Meridian Contrarian Fund
$17.5M position · as of 2026-06-30
2.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $220.0K sold by insiders over 180 days, 203 funds added last quarter, $220.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
NVST financials
Revenue growth
+8.3%
XBRL, annual
Net margin
1.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.9B
four quarters, 2025-06-28 to 2026-07-03
Revenue, TTM NVST
| FY Dec 2025 | $2.7B |
| FY Dec 2024 | $2.5B |
| FY Dec 2023 | $2.6B |
| FY Dec 2022 | $2.6B |
| FY Dec 2021 | n/a |
| Jul 2026 | $730.5M |
| Apr 2026 | $705.5M |
| Dec 2025 | $750.6M |
| Sep 2025 | $669.9M |
| Jun 2025 | $682.1M |
| Mar 2025 | $616.9M |
| Dec 2024 | $652.9M |
| Sep 2024 | $601.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+3.3%
net income over revenue, 2025-06-28 to 2026-07-03
Net margin, TTM NVST
| FY Dec 2025 | +1.7% |
| FY Dec 2024 | -44.6% |
| FY Dec 2023 | -3.9% |
| FY Dec 2022 | +9.5% |
| FY Dec 2021 | n/a |
| Jul 2026 | +7.4% |
| Apr 2026 | +5.5% |
| Dec 2025 | +4.4% |
| Sep 2025 | -4.5% |
| Jun 2025 | +3.9% |
| Mar 2025 | +2.9% |
| Dec 2024 | +0.2% |
| Sep 2024 | +1.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$248.1M
operating cash flow minus capex, 2025-06-28 to 2026-07-03
Free cash flow, TTM NVST
| FY Dec 2025 | $230.4M |
| FY Dec 2024 | $302.7M |
| FY Dec 2023 | $217.5M |
| FY Dec 2022 | $107.0M |
| FY Dec 2021 | $306.9M |
| Jul 2026 | $104.3M |
| Apr 2026 | -$15.8M |
| Dec 2025 | $91.7M |
| Sep 2025 | $67.9M |
| Jun 2025 | $76.4M |
| Mar 2025 | -$5.6M |
| Dec 2024 | $123.8M |
| Sep 2024 | $63.3M |
At each fiscal year end
Single quarter
Debt to equity
0.47x
long-term 2026-07-03 plus current 2025-12-31 (6 months older than the period end); equity 2026-07-03
Debt to equity NVST
| FY Dec 2025 | 0.47x |
| FY Dec 2024 | 0.48x |
| FY Dec 2023 | 0.36x |
| FY Dec 2022 | 0.33x |
| FY Dec 2021 | 0.32x |
| Jul 2026 | 0.47x |
| Apr 2026 | 0.47x |
| Dec 2025 | 0.47x |
| Sep 2025 | 0.47x |
| Jun 2025 | 0.46x |
| Mar 2025 | 0.47x |
| Dec 2024 | 0.48x |
| Sep 2024 | 0.46x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.21x
TTM operating cash flow over long-term 2026-07-03 plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt NVST
| FY Dec 2025 | 0.19x |
| FY Dec 2024 | 0.24x |
| FY Dec 2023 | 0.18x |
| FY Dec 2022 | 0.13x |
| FY Dec 2021 | 0.27x |
| Jul 2026 | 0.21x |
| Apr 2026 | 0.19x |
| Dec 2025 | 0.19x |
| Sep 2025 | 0.21x |
| Jun 2025 | 0.20x |
| Mar 2025 | 0.21x |
| Dec 2024 | 0.24x |
| Sep 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+3.1%
TTM net income over average of 2025-06-27 and 2026-07-03
Return on equity NVST
| FY Dec 2025 | +1.6% |
| FY Dec 2024 | -31.5% |
| FY Dec 2023 | -2.4% |
| FY Dec 2022 | +5.9% |
| FY Dec 2021 | +8.8% |
| Jul 2026 | +3.1% |
| Apr 2026 | +2.2% |
| Dec 2025 | +1.6% |
| Sep 2025 | +0.5% |
| Jun 2025 | +1.8% |
| Mar 2025 | -31.3% |
| Dec 2024 | -31.5% |
| Sep 2024 | -36.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.7%
TTM net income over average of 2025-06-27 and 2026-07-03
Return on assets NVST
| FY Dec 2025 | +0.9% |
| FY Dec 2024 | -18.7% |
| FY Dec 2023 | -1.5% |
| FY Dec 2022 | +3.7% |
| FY Dec 2021 | +5.1% |
| Jul 2026 | +1.7% |
| Apr 2026 | +1.2% |
| Dec 2025 | +0.9% |
| Sep 2025 | +0.3% |
| Jun 2025 | +1.0% |
| Mar 2025 | -18.7% |
| Dec 2024 | -18.7% |
| Sep 2024 | -21.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate 59%, not meaningful
Return on invested capital NVST
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +5.7% |
| FY Dec 2021 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.7%
operating income (EBIT proxy) over average of 2025-06-27 and 2026-07-03 minus current liabilities
Return on capital employed NVST
| FY Dec 2025 | +4.6% |
| FY Dec 2024 | -20.2% |
| FY Dec 2023 | +0.6% |
| FY Dec 2022 | +6.0% |
| FY Dec 2021 | +5.8% |
| Jul 2026 | +5.7% |
| Apr 2026 | +5.1% |
| Dec 2025 | +4.6% |
| Sep 2025 | +4.0% |
| Jun 2025 | +3.2% |
| Mar 2025 | -20.2% |
| Dec 2024 | -20.2% |
| Sep 2024 | -24.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
40.69x
close 2026-10-23 over four quarters of diluted EPS, 2025-06-28 to 2026-07-03
P/E, trailing NVST
| FY Dec 2025 | 77.54x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 24.58x |
| FY Dec 2021 | 26.82x |
| Jul 2026 | 47.64x |
| Apr 2026 | 62.95x |
| Dec 2025 | 77.54x |
| Sep 2025 | 226.11x |
| Jun 2025 | 61.47x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.1B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-07-03 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-07-03
Enterprise value NVST
| FY Dec 2025 | $3.8B |
| FY Dec 2024 | $3.6B |
| FY Dec 2023 | $4.7B |
| FY Dec 2022 | $6.3B |
| FY Dec 2021 | $7.5B |
| Jul 2026 | $4.8B |
| Apr 2026 | $4.6B |
| Dec 2025 | $3.8B |
| Sep 2025 | $3.7B |
| Jun 2025 | $3.7B |
| Mar 2025 | $3.3B |
| Dec 2024 | $3.6B |
| Sep 2024 | $3.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.5%
TTM free cash flow over market value at close 2026-10-23
FCF yield NVST
| FY Dec 2025 | +6.5% |
| FY Dec 2024 | +9.1% |
| FY Dec 2023 | +5.3% |
| FY Dec 2022 | +1.9% |
| FY Dec 2021 | +4.2% |
| Jul 2026 | +5.5% |
| Apr 2026 | +5.2% |
| Dec 2025 | +6.5% |
| Sep 2025 | +7.8% |
| Jun 2025 | +7.7% |
| Mar 2025 | +9.2% |
| Dec 2024 | +9.1% |
| Sep 2024 | +8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.50x
P/E over trailing EPS growth of 81%: four quarters to 2026-07-03 against the four to 2025-06-27
PEG, trailing NVST
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.04x |
| Jul 2026 | 0.59x |
| Apr 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.7B | $2.5B | $2.6B | $2.6B |
| Gross profit | $1.5B | $1.4B | $1.4B | $1.5B |
| Operating income | $216.1M | -$1.0B | $31.5M | $319.2M |
| Net income | $47.0M | -$1.1B | -$100.2M | $243.1M |
| EPS (diluted) | 0.28 | -6.50 | -0.60 | 1.37 |
| Operating cash flow | $275.7M | $336.5M | $275.7M | $182.7M |
| Cash | $1.2B | $1.1B | $940.0M | $606.9M |
| Long-term debt | $1.4B | $1.3B | $1.4B | $870.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
NVST Stock Sonar score 6/7 axes
Find similar shapesCompareNVST ranks highest on profitability (74th percentile) and risk and compliance (71st), and lowest on insider conviction (1st), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NVST filings, in plain words
Are Envista insiders buying or selling NVST?
In the 180 days to 2026-10-28, Envista insiders were net sellers, a net $220.0K across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded NVST?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Pete Sessions dated 2024-06-06.
Are there planned insider sales of NVST?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $220.0K of stock; the latest, by Reis Mischa, was filed 2026-08-20.
Read the full summary
In the 180 days to 2026-10-28, Envista insiders were net sellers of NVST, a net $220.0K across purchases and sales reported on Form 4 by 1 seller. Members of Congress have disclosed trades in NVST, none in the last year; the latest on record is a sale by Pete Sessions dated 2024-06-06. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $220.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
